Business Description
Grifols SA
ISIN : US3984384087
Share Class Description:
GRFS: ADRTotal Employee Number:
25,247Description
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.06 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 1.54 | |||||
Debt-to-EBITDA | 5.35 | |||||
Interest Coverage | 2.5 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.05 | |||||
Beneish M-Score | -2.61 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.4 | |||||
3-Year EBITDA Growth Rate | 11.1 | |||||
3-Year EPS without NRI Growth Rate | 35.3 | |||||
3-Year Book Growth Rate | -2.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 21.96 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.47 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.95 | |||||
9-Day RSI | 54.47 | |||||
14-Day RSI | 54.83 | |||||
3-1 Month Momentum % | -4.44 | |||||
6-1 Month Momentum % | -17.55 | |||||
12-1 Month Momentum % | -23.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.37 | |||||
Quick Ratio | 0.81 | |||||
Cash Ratio | 0.24 | |||||
Days Inventory | 264.51 | |||||
Days Sales Outstanding | 38.85 | |||||
Days Payable | 70.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.32 | |||||
Dividend Payout Ratio | 0.37 | |||||
Forward Dividend Yield % | 3.52 | |||||
5-Year Yield-on-Cost % | 1.32 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 4.44 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 37 | |||||
Operating Margin % | 16.24 | |||||
Net Margin % | 6.11 | |||||
EBITDA Margin % | 21.47 | |||||
FCF Margin % | 8.71 | |||||
OCF Margin % | 14.77 | |||||
ROE % | 8.51 | |||||
ROA % | 2.28 | |||||
ROIC % | 5.29 | |||||
3-Year ROIIC % | -23.71 | |||||
ROC (Joel Greenblatt) % | 18.48 | |||||
ROCE % | 6.47 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 14.88 | |||||
Forward PE Ratio | 7.32 | |||||
PE Ratio without NRI | 14.88 | |||||
Shiller PE Ratio | 11.66 | |||||
Price-to-Owner-Earnings | 12.87 | |||||
PEG Ratio | 2.44 | |||||
PS Ratio | 0.91 | |||||
PB Ratio | 1.22 | |||||
Price-to-Free-Cash-Flow | 10.48 | |||||
Price-to-Operating-Cash-Flow | 6.17 | |||||
EV-to-EBIT | 14.24 | |||||
EV-to-Forward-EBIT | 17.51 | |||||
EV-to-EBITDA | 10.29 | |||||
EV-to-Forward-EBITDA | 12.04 | |||||
EV-to-Revenue | 2.21 | |||||
EV-to-Forward-Revenue | 2.47 | |||||
EV-to-FCF | 25.47 | |||||
Price-to-GF-Value | 0.93 | |||||
Price-to-Projected-FCF | 0.88 | |||||
Price-to-DCF (Earnings Based) | 0.83 | |||||
Price-to-DCF (FCF Based) | 0.58 | |||||
Price-to-Median-PS-Value | 0.3 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.37 | |||||
Earnings Yield (Greenblatt) % | 7.02 | |||||
FCF Yield % | 10.78 | |||||
Forward Rate of Return (Yacktman) % | 15.7 |
Grifols SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Grifols SA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 18:30 | In 75 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 73 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-28 18:30 | 7.75 (+0.39%) | ||
| Second quarter earnings results for 2026 | 2026-07-28 17:35 | 7.75 (+0.39%) | ||
| USD 0.105816 Cash Dividend | 2026-07-02 | 7.08 (-0.28%) | ||
| General meeting for 2026 | 2026-06-17 12:00 | 7.59 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 12:30 | 8.41 (+0.12%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 8.41 (+0.12%) | ||
| Annual report for 2025 | 2026-02-27 | 8.96 (-0.78%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 12:30 | 9.25 (+1.20%) |
Show
Entries
Press Release
Articles on Grifols SA
Brandes Investment Partners, LP's Top Q2 2026 Move: CNH Industrial NV at a 1.51% Portfolio Impact
Aug 14, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers